Skip to main content
Caplight Logo









Chengdu NewRT Medical Technology

Chengdu NewRT Medical Technology

Private
ChengduHealthcare & Life Scienceshttps://nrtmedtech.com/

Last Round

Series E

Apr 3, 2026

Est. Valuation

$110M

Total Funding Raised

$313.17M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Chengdu NewRT Medical Technology is a biotechnology company that develops and produces medical isotopes and radiopharmaceuticals for the diagnosis and treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical Devices, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

radiopharmaceuticalsradioligand therapyRLTmedical isotopestheranosticsisotope productionFAP targeted therapynuclear medicinetargeted radionuclide therapycancer therapyGallium-68 generatorCDMO servicescontract development and manufacturing organizationinterventional oncologyLutetium-177Yttrium-90 microsphereActinium-225

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Chengdu NewRT Medical Technology Comparables

Compare Chengdu NewRT Medical Technology with similar companies based on industry and business-model similarity.

Chengdu NewRT Medical Technology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Yantai Dongcheng Pharmaceutical Group Co., Ltd.
82%
Eli Lilly and Company
82%
C-Ray Therapeutics
78%

Chengdu NewRT Medical Technology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series EApr 3, 2026
Series DOct 10, 2025
Series CMar 14, 2024
Series BJul 16, 2019

Chengdu NewRT Medical Technology Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 399, 4433% of headcount.

  • Jul 13, 2026

    Open roles increased to 332, 3.8x the trailing average.

Chengdu NewRT Medical Technology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Chengdu NewRT Medical Technology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Chengdu NewRT Medical Technology's valuation, stock price, and market status.

Firmographic Details

HeadquartersChengdu
Employee Range9
Year Founded2016
Last FundingApr 3, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?